AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
IMCLONE rose after Medicare officials proposed paying for some colon cancer drugs, including ImClone Systems' Erbitux and Genentech's Avastin, when used during clinical studies to treat other kinds of cancer.
FOREST LABS cut its '05 profit outlook to $2.50 a share vs. $2.63 expected, citing the recent introduction of generic versions of its antidepressant Celexa. Shares fell.
MACROVISION warned it will make 25-27 cents a share ex items in Q4 vs. views of 28 ...